开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-07-23 ms4000000387006148 来自江苏省

审稿速度:3.0 | 投稿命中率:75.0
偏重的研究方向：糖尿病
经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。

Submission status Date
Submission received
25 Apr 2024
Technical check
Submission status Date
Submission is under technical check
25 Apr 2024
Submission passed technical check
26 Apr 2024
Editorial assignment
Submission status Date
Ready for editorial assignment
26 Apr 2024
With editor
Submission status Date
Editor assigned
26 Apr 2024
Peer review
Submission status Date
Submission under peer review
07 May 2024
Revision requested
18 Jun 2024
Revision received
26 Jun 2024
Submission passed technical check
27 Jun 2024
Submission accepted
Submission status Date
Submission accepted
18 Jul 2024
Publishing and rights
Submission status Date
Submission is in publishing and rights
22 Jul 2024
Production
Submission status Date
Publishing and rights complete
23 Jul 2024

38 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2024-02-29 苦行僧难上加难来自安大略

昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？

77 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-09-26 ms4000001372213942 来自陕西省

审稿速度:3.0 | 投稿命中率:50.0
经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀

96 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-11-27 1df0083fm15(暂无匿称) 来自广东省

审稿速度:2.0 | 投稿命中率:50.0
经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。

77 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-05-06 zwwandzl 来自北京

审稿速度:2.0 | 投稿命中率:95.0
偏重的研究方向：糖尿病心肌病;药物治疗
经验分享：3.19投稿
4.14接收
5.6online

110 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-11-30 1471fd7fm79暂无昵称来自辽宁省

记录一下 11.30投稿 3分钟😂 正在initial technical check中

79 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2023-01-01 ms9000001742428006 来自广东省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：炎症;糖尿病;冠心病
经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！

123 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-03-01 梁小猪

审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0
偏重的研究方向：diabetes;metabolic syndrome
经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作

282 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2022-10-19 祈祈祈祈祈丷

偏重的研究方向：Diabetes
经验分享：20分钟秒拒🍉🍉🍉

130 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2216387, encodeId=cbd4221638eb4, content=审稿速度:3.0 | 投稿命中率:75.0 偏重的研究方向：糖尿病 经验分享：还是比较快的。3个月接受。审稿速度感觉看运气。 Submission status Date Submission received 25 Apr 2024 Technical check Submission status Date Submission is under technical check 25 Apr 2024 Submission passed technical check 26 Apr 2024 Editorial assignment Submission status Date Ready for editorial assignment 26 Apr 2024 With editor Submission status Date Editor assigned 26 Apr 2024 Peer review Submission status Date Submission under peer review 07 May 2024 Revision requested 18 Jun 2024 Revision received 26 Jun 2024 Submission passed technical check 27 Jun 2024 Submission accepted Submission status Date Submission accepted 18 Jul 2024 Publishing and rights Submission status Date Submission is in publishing and rights 22 Jul 2024 Production Submission status Date Publishing and rights complete 23 Jul 2024 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=adf06405121, createdName=ms4000000387006148, createdTime=Tue Jul 23 09:56:04 CST 2024, time=2024-07-23, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2190116, encodeId=c5f421901169c, content=昨天都显示40 reviewers invited，今天显示ready to be assigned to an editor，有大佬解释一下这是什么情况吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c6f15450000, createdName=苦行僧难上加难, createdTime=Thu Feb 29 15:32:13 CST 2024, time=2024-02-29, status=1, ipAttribution=安大略), GetPortalCommentsPageByObjectIdResponse(id=2159883, encodeId=824921598833d, content=审稿速度:3.0 | 投稿命中率:50.0 经验分享：同行评审两个月了，还没有消息，有同样的友友吗，会不会拒了呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b3708444503, createdName=ms4000001372213942, createdTime=Tue Sep 26 21:16:44 CST 2023, time=2023-09-26, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2171368, encodeId=fa6721e136863, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：4月投稿，7月还没动静，催。见编辑部发出40封审稿函，终于找到审稿人。两人审，两轮修。10月接受，11月online。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=77, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fec61737533, createdName=1df0083fm15(暂无匿称), createdTime=Mon Nov 27 22:40:24 CST 2023, time=2023-11-27, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2130646, encodeId=417d2130646e9, content=审稿速度:2.0 | 投稿命中率:95.0 偏重的研究方向：糖尿病心肌病;药物治疗 经验分享：3.19投稿 4.14接收 5.6online, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=110, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLmtjiaJlQy9E4hZZuOBFtXHuDIFe2qMhzVwfETPk9ZH3MpEx13gGh5g86Iowu0B1aoWoiaGs6wKy8g/132, createdBy=191c2432552, createdName=zwwandzl, createdTime=Sat May 06 23:27:39 CST 2023, time=2023-05-06, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2172188, encodeId=1ee821e2188e4, content=记录一下 11.30投稿 3分钟😂 正在initial technical check中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=79, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=082f5193268, createdName=1471fd7fm79暂无昵称, createdTime=Thu Nov 30 19:06:47 CST 2023, time=2023-11-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2108434, encodeId=4cb72108434ad, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：炎症;糖尿病;冠心病 经验分享：10月中旬投的，11月初邀请审稿人审稿，11月底收到2个审稿人意见，期间经历3次大修，平均8天收到一次审稿意见，最终在2022年12月29接收，划上圆满句号！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b90a5434266, createdName=ms9000001742428006, createdTime=Sun Jan 01 20:11:11 CST 2023, time=2023-01-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=944432, encodeId=f11194443255, content=审稿速度:1.0 | 投稿命中率:50.0 | 版面费用:2380.0 偏重的研究方向：diabetes;metabolic syndrome 经验分享：返修速度还可以，修回到接收快到飞起，简直难以置信是外国人在工作, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=282, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79122109984, createdName=梁小猪, createdTime=Mon Mar 01 13:44:03 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094700, encodeId=9cca2094e0066, content=偏重的研究方向：Diabetes 经验分享：20分钟秒拒🍉🍉🍉, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200630/0b394d14a5624701979051aee2b9d6bf/5f7b4cc07a0f495c8a29b0330c7b5232.jpg, createdBy=d4d12391437, createdName=祈祈祈祈祈丷, createdTime=Wed Oct 19 12:05:20 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1104225, encodeId=9647110422575, content=什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=)]

2021-12-28 Mia

什么是期刊编辑的意见和建议？什么是评审/审稿人/reviewer的意见和建议？两者有什么不同？

0 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务